ensaculin has been researched along with Dementia in 2 studies
*Dementia: An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hoerr, R; Noeldner, M | 1 |
| Biber, A; Derendorf, H; Hoerr, R; Sourgens, H; Steinbrede, H | 1 |
1 review(s) available for ensaculin and Dementia
| Article | Year |
|---|---|
Ensaculin (KA-672 HCl): a multitransmitter approach to dementia treatment.
Topics: Animals; Benzopyrans; Clinical Trials as Topic; Dementia; Humans; Memory; Neuroprotective Agents; Piperazines; Receptors, Adrenergic, alpha-1; Receptors, Dopamine D2; Receptors, Dopamine D3; Receptors, N-Methyl-D-Aspartate; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Synaptic Transmission | 2002 |
1 trial(s) available for ensaculin and Dementia
| Article | Year |
|---|---|
KA 672-HCl, a neuronal activator against dementia: tolerability, safety, and preliminary pharmacokinetics after single and multiple oral doses in healthy male and female volunteers.
Topics: Administration, Oral; Aged; Benzopyrans; Dementia; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines | 1998 |